P3 Health Partners Inc. (PIII) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: some financial improvements, but ongoing challenges. The company shows a slight improvement in EBITDA and revenue, but liquidity risks and declining medical margins are concerning. The Q&A reveals that new agreements like the Nebraska deal could bring future growth, but execution risks remain. Overall, the positive aspects are balanced by significant uncertainties, leading to a neutral sentiment.
Key Financial Performance
Adjusted EBITDA (2025) Negative $161.3 million, compared to a loss of $167.2 million in 2024. On a normalized basis, the loss was $149.1 million in 2025, compared to $193.0 million in 2024, reflecting a $44 million improvement year-over-year. The improvement was driven by stronger contracting economics, improved provider alignment, and structural cost actions.
Total Revenue (Q4 2025) $384.8 million, compared to $370.7 million in Q4 2024, showing an increase. The increase was attributed to improved burden of illness documentation, strengthened contractual economics, and membership mix.
Capitated Revenue PMPM (Q4 2025) $1,060, compared to $971 in Q4 2024, a 9% improvement. This was due to continued improvement in burden of illness documentation, strengthened contractual economics, and membership mix.
Total Revenue (Full Year 2025) $1.46 billion, compared to $1.50 billion in 2024, showing a slight decline.
Capitated Revenue PMPM (Full Year 2025) $1,026, compared to $981 in 2024, a 5% improvement. This was driven by improved burden of illness documentation, strengthened contractual economics, and membership mix.
Medical Margin (Q4 2025) Negative $28.7 million or negative $83 PMPM, compared to $7.3 million or $19 PMPM in Q4 2024, showing a decline.
Medical Margin (Full Year 2025) $23.5 million or $17 PMPM, compared to $85.4 million or $56 PMPM in 2024, showing a decline. On a normalized basis, it was $52.3 million or $38 PMPM in 2025, compared to $51.4 million or $34 PMPM in 2024, reflecting a slight improvement.
Operating Expense (Q4 2025) $35.1 million, compared to $28.7 million in Q4 2024, showing an increase. The increase included a $10 million reclassification of network expense to operating expense related to third-party vendor costs.
Operating Expense (Full Year 2025) $101.8 million, compared to $111.8 million in 2024, a reduction of $10 million or 9% year-over-year. This was due to structural cost actions, including reductions in duplicate corporate infrastructure, tighter discretionary spending controls, and improved market-level accountability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Medicare Advantage geography expansion: P3 Health Partners announced a partnership expanding their presence into a new Medicare Advantage geography, adding 29,000 new members under management. This represents a 25% in-year growth and is expected to contribute $27 million in revenue for 2026. The partnership includes a multiyear glide path to risk, potentially equating to over $300 million in revenue upon moving to full risk.
Operational improvement opportunities: Identified $170 million in structural and operational improvement opportunities for 2026. This includes $125 million from contracting and revenue-related actions, $35 million from operational execution around MedEx initiatives and network contracting, and $10 million from payer benefit design collaboration and membership profile.
Provider alignment and quality improvement: Improved contracts, increased provider alignment, and achieved 4-star status across 70% of priority Medicare Advantage plans. More than half of patients are now served by Tier 1 provider groups with higher clinical integration and accountability.
Cost structure and operational discipline: Reduced operating expenses by $10 million year-over-year in 2025 through structural cost actions, tighter discretionary spending controls, and improved market-level accountability. Reinvested selectively in market operations, provider support, and care coordination functions.
Care enablement model: Focused on embedding care coordination, utilization management, and quality support within provider practices to manage higher-risk patients effectively. Expanded complex care programs for patients with advanced chronic conditions.
Disciplined growth strategy: Adopted a phased glide path approach for entering new geographies, reducing volatility and supporting financial performance during the ramp period. This strategy ensures operational execution foundations are established before assuming full risk.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance: The company reported a significant adjusted EBITDA loss of $161.3 million for 2025, reflecting ongoing financial challenges. Despite improvements, the financial trajectory remains a concern with a reliance on future cost management and contract renegotiations to achieve profitability.
Operational Execution: The company faces risks in executing operational improvements, including medical cost management and renegotiation of underperforming contracts. The timing and success of these initiatives are critical to achieving the projected financial improvements for 2026.
Liquidity Position: The company ended 2025 with only $25 million in cash on hand, highlighting potential liquidity risks. This limited cash reserve could constrain operational flexibility and investment capacity.
Market Expansion: The company’s expansion into a new Medicare Advantage geography involves a phased glide path to full risk. While this approach reduces volatility, it introduces risks related to operational execution and financial performance during the ramp-up period.
Provider Alignment: The company’s reliance on Tier 1 provider networks and the need for continued alignment pose risks. Any misalignment or underperformance in these networks could adversely impact clinical outcomes and cost management.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Adjusted EBITDA Guidance: The company is guiding to an adjusted EBITDA at a midpoint of $10 million, a significant improvement from the 2025 adjusted EBITDA loss of $161 million. This improvement is supported by $170 million in structural and operational improvements, including $125 million from contracting and revenue-related actions, $35 million from operational execution, and $10 million from payer benefit design collaboration.
Revenue Growth from New Partnership: The company announced a partnership expanding into a new Medicare Advantage geography, adding 29,000 new members under management. This represents 25% in-year growth and is expected to contribute $27 million in revenue for 2026. The partnership includes a multiyear glide path to risk, potentially equating to over $300 million in revenue upon moving to full risk.
2026 Revenue and Membership Outlook: The company expects total revenue in the range of $1.5 billion to $1.7 billion and at-risk membership between 107,000 to 117,000 members in 2026. The range reflects the timing of execution of key initiatives.
Medical Cost Management Initiatives: Multiple initiatives are underway to manage medical costs, with benefits expected to build as programs scale throughout 2026. These include post-acute management, chronic care management, and specialty utilization oversight.
Operational and Contractual Improvements: The company plans to continue evaluating and renegotiating underperforming contract arrangements and progressing towards full delegation where appropriate. These actions are expected to contribute to financial performance improvements in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On the risk member guidance midpoint of 112,000, are the 140,000 members from the new Nebraska agreement included in the 112,000 or are they extra?
A:The 140,000 members from the Nebraska agreement are extra. The 112,000 are full-risk members, and the Nebraska lives are an additional 29,000 lives under management.
Q:What kind of stand-up costs or geo-entry costs are needed to move into the new Nebraska geography?
A:The economics of the deal allow for funding to cover the stand-up costs. Some of the infrastructure already built within P3 will also be utilized.
Q:Can you provide a sense of how much of the $170 million improvement is run rate entering the year versus what still needs to be activated in 2026?
A:About 75% of the $170 million improvement is run rate starting in January, focusing on revenue from contract updates, pop increases, and CMS benchmark increases. 20% is operational and being executed through initiatives like MedEx, and a small portion comes from benefit design and membership mix adjustments in 2026.
Q:How is the company interacting with the Nebraska Blues plan for the first 2 years, and are there metrics to convert to full risk in 2028?
A:The company has a 2-year fee-for-service glide path to risk, contractually set to convert to full risk in 2028. There are performance metrics within the contract related to value creation for the client.
Q:What are some tangible examples of changes in the 2026 contracts compared to 2025, aside from CMS rate updates?
A:Changes include adjustments in premium amounts, reduction of duplicate costs where services were already provided by P3, and improvements in stars performance, which impact plan revenue and are reflected in contract adjustments.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were direct and provided sufficient detail.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advantage geography
Advantage plan
Gabby
Medicare Advantage
Number
PMPM improvement
accountability
area
care coordination
contracting
core
cost action
cost structure
discipline
economics
foundation
glide path
insight
margin PMPM
midpoint improvement
oversight
path risk
pathway
patient condition
payer
provider alignment
provider practice
provider support
reclassification
renegotiations
risk membership
specialty
stability
timing
today result
trajectory
visibility improvement
work
PIII Transcript
P3 Health Partners Inc. (PIII) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance with a 25% increase in adjusted EBITDA and a 10% increase in medical margin. Despite a slight decline in cash flow, the overall financial health appears robust. The new partnership contributing to revenue growth and a positive outlook for 2026 further support a positive sentiment. The lack of discussion on strategic initiatives and operational updates does not overshadow the strong financial metrics and optimistic guidance, suggesting a likely stock price increase in the short term.
P3 Health Partners Inc. (PIII) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call summary presents a mixed picture: some financial improvements, but ongoing challenges. The company shows a slight improvement in EBITDA and revenue, but liquidity risks and declining medical margins are concerning. The Q&A reveals that new agreements like the Nebraska deal could bring future growth, but execution risks remain. Overall, the positive aspects are balanced by significant uncertainties, leading to a neutral sentiment.
P3 Health Partners Inc. (PIII) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call highlighted liquidity concerns, reliance on external factors for growth, and a broad-based guidance reduction due to underperformance. Despite some operational improvements, the Q&A revealed management's vague responses to critical questions, raising uncertainties. The company's cash position and dependency on future joint ventures further add to the negative sentiment. The negative aspects outweigh the positive, suggesting a negative stock price reaction in the short term.
P3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture: strong operational improvements and a positive outlook for 2025, including breakeven achievements and renegotiation progress, are offset by current losses and adjustments impacting financials negatively. The Q&A reveals management's confidence in overcoming past issues but also highlights uncertainties in guidance and market performance. The lack of clear responses to some analyst questions further tempers optimism. Given these factors, the stock price is likely to remain stable in the short term, with potential for improvement as execution on strategies progresses.
PIII Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
